ArticleJournal of nanobiotechnology2025

Hypoxia-activated paclitaxel prodrugs enable PD-L1 degradation to potentiate cancer chemo-immunotherapy.

Shiyu Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.